EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?

Dominik Kylies, Leonie Dreher, Ulrich O Wenzel

Current Hypertension Reports · 07.05.2026 · 28 (1)

DOI: 10.1007/s11906-026-01374-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Hypertension Reports, online erschienen am 07.05.2026. Verfasst von Dominik Kylies und 2 weiteren Autor:innen. Beteiligte Einrichtung: III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Hypertension, Incretins, Antihypertensive Agents, Blood Pressure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Hamburg-Eppendorf (UKE).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose of Review This review evaluates the antihypertensive potential of next-generation incretin-based therapies, including GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists. It examines their effects on blood pressure reduction, underlying mechanisms, clinical benefits, and implications for future guidelines. Recent Findings Recent large-scale trials demonstrate that incretin-based therapies such as semaglutide and tirzepatide significantly reduce body weight, blood pressure, and cardiovascular outcomes. Mediation analyses indicate that weight loss explains a substantial proportion of blood pressure reduction, while direct effects on vascular function, renal sodium handling, and neurohumoral pathways also contribute. These effects are consistent across diverse populations, including individuals without overt hypertension. Summary Incretin-based therapies represent a promising approach in hypertension management, combining metabolic and cardiovascular benefits. Despite the lack of trials with blood pressure as a primary endpoint, current evidence supports their use in selected high-risk populations and suggests an emerging role in future guideline recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionIncretinsAntihypertensive AgentsBlood PressureHumansGlucagon-Like Peptide-1 Receptor AgonistsSemaglutideTirzepatideReceptors, Gastrointestinal Hormone

Stichwörter der Autor:innen

Blood pressure reductionHypertension managementIncretin-based therapiesWeight loss–independent mechanisms

Substanzen

IncretinsAntihypertensive AgentsGlucagon-Like Peptide-1 Receptor AgonistsSemaglutideTirzepatideReceptors, Gastrointestinal Hormone

Autor:innen und Institutionen

  • III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg- Eppendorf, Hamburg, Germany.
  • III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. wenzel@uke.de.
  • Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg- Eppendorf, Hamburg, Germany. wenzel@uke.de.

Förderung

  • Universitätsklinikum Hamburg-Eppendorf (UKE)

Zitieren

APA

Kylies, D., Dreher, L., & Wenzel, U. O. (2026). Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?. Current Hypertension Reports, 28(1). https://doi.org/10.1007/s11906-026-01374-7

Vancouver

Kylies D, Dreher L, Wenzel UO. Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?. Current Hypertension Reports. 2026;28(1). doi:10.1007/s11906-026-01374-7

BibTeX
@article{Kylies2026,
  author = {Kylies, Dominik and Dreher, Leonie and Wenzel, Ulrich O},
  title = {Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?},
  journal = {Current Hypertension Reports},
  year = {2026},
  volume = {28},
  number = {1},
  doi = {10.1007/s11906-026-01374-7}
}
Kostenlos starten →